|
OMIM |
Link |
Information gain |
01 |
|
XDH
|
[NCBI]
|
0.00320212
|
|
|
poland syndrome
|
[NCBI]
|
0.00277021
|
|
|
LNS
|
[NCBI]
|
0.000534343
|
|
|
phosphoribosylpyrophosphate synthetase superactivity
|
[NCBI]
|
0.000346581
|
|
|
APRT
|
[NCBI]
|
0.000295061
|
|
|
severe cutaneous adverse reaction, susceptibility to
|
[NCBI]
|
0.000254432
|
|
|
HNFJ
|
[NCBI]
|
0.000202522
|
|
|
hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase
|
[NCBI]
|
0.000180991
|
|
|
CAT
|
[NCBI]
|
0.000123946
|
|
|
gout, hprt-related
|
[NCBI]
|
0.00011236
|
|
|
MPO
|
[NCBI]
|
0.000101352
|
|
|
xanthinuria, type i
|
[NCBI]
|
9.445e-05
|
|
|
uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to
|
[NCBI]
|
9.06659e-05
|
|
|
UOX
|
[NCBI]
|
8.84563e-05
|
|
|
molybdenum cofactor deficiency
|
[NCBI]
|
8.64449e-05
|
|
|
hyperoxaluria, primary, type i
|
[NCBI]
|
7.91265e-05
|
|
|
lymphoma, non-hodgkin, familial
|
[NCBI]
|
7.11158e-05
|
|
|
ornithine transcarbamylase deficiency, hyperammonemia due to
|
[NCBI]
|
5.93945e-05
|
|
|
RA
|
[NCBI]
|
4.36477e-05
|
|
|
HPRT1
|
[NCBI]
|
4.10426e-05
|
|
|
BL
|
[NCBI]
|
4.06468e-05
|
|
|
EGF
|
[NCBI]
|
2.68775e-05
|
|
|
SLE
|
[NCBI]
|
2.37714e-05
|
|
|
MOCS1
|
[NCBI]
|
2.34962e-05
|
|
|
AGXT
|
[NCBI]
|
1.85411e-05
|
|
|
TNF
|
[NCBI]
|
1.73105e-05
|
|
|
HLA-B
|
[NCBI]
|
1.48124e-05
|
|
|
RPGR
|
[NCBI]
|
1.18345e-05
|
|
|
TPMT
|
[NCBI]
|
8.08732e-06
|
|
|
MCP
|
[NCBI]
|
6.14711e-06
|
|
|
ACHE
|
[NCBI]
|
5.43939e-06
|
|
|
AVP
|
[NCBI]
|
4.78706e-06
|
|
|
KLK3
|
[NCBI]
|
4.63403e-06
|
|
|
CCK
|
[NCBI]
|
3.7105e-06
|
|
|
MBL2
|
[NCBI]
|
3.41535e-06
|
|
|
GJA1
|
[NCBI]
|
3.2706e-06
|
|
|
CTGF
|
[NCBI]
|
1.65654e-06
|
|
|
PTH
|
[NCBI]
|
1.00843e-06
|
|
|
SPP1
|
[NCBI]
|
2.69424e-07
|
|
|
VIP
|
[NCBI]
|
2.40108e-07
|
|
|
PPARA
|
[NCBI]
|
2.38807e-07
|
|
|
ADA
|
[NCBI]
|
1.08233e-08
|
|